As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that policymakers set clear elimination targets for hepatitis B, coordinate efforts, enhance surveillance, and create supportive regulatory environments to support this.

Medically reviewed by Patricia Mikula, PharmD Key Takeaways Most people who get the hepatitis B vaccine have protection for their whole life.People on dialysis or those who don't respond to the vaccine might need a booster.

APhA also underscores the importance of hepatitis B vaccination in adulthood. ACIP continues to recommend the vaccine series for all adults ages 19--59 years, adults 60 years and older with risk factors, and any adult who requests vaccination. Hepatitis B vaccines are safe, effective, and covered by insurance.

Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug. At the heart of the deal is brelovitug, an immunoglobulin G1 monoclonal antibody that targets the surface antigen on both the chronic hepatitis D virus (HDV) and the hepatitis B virus (HBV).